Bharat Majeti

Bharat Majeti has had a long and varied career in the pharmaceutical industry. Bharat began their career in 2000 as a Graduate Student at the Indian Institute of Chemical Technology, where they designed, synthesized, and formulated novel cationic lipids and tumor targeting lipopeptides. Bharat then moved to UC San Diego in 2005, where they worked as a Postdoctoral Scientist and developed nanoparticle mediated drug delivery systems to target tumor vasculature and metastasis. In 2010, they joined Pfizer Inc. as a Postdoctoral Scientist, where they developed a targeted lipid based nanoparticle as an imaging tool for non-invasive imaging of VEGFR2 and ALK1 expression levels on tumor endothelial cells. In 2013, they moved to Nitto Denko Technical Corporation as a Principal Scientist and Senior Scientist. In 2016, they joined Nitto BioPharma as a Principal Scientist I, and in 2018, they were promoted to Principal Scientist II. In 2019, they were promoted to Senior Director and Director at Nitto BioPharma Inc. Bharat is currently Vice President at RVAC Medicines, a position they have held since 2022.

Bharat Majeti began their educational journey by obtaining a Master of Science (MS) degree from the University of Hyderabad in the field of Chemistry. Bharat then went on to pursue a Ph.D. in Chemistry and Chemical Biology from the Indian Institute of Chemical Technology. After completing their Ph.D., they returned to the University of Hyderabad to obtain a M.Sc. in the field of Chemistry. Bharat then went back to the Indian Institute of Chemical Technology to pursue a Ph.D. in Chemical Biology. Bharat currently attends the University of California, San Diego School of Medicine.